HANGZHOU, China, June 30, 2026, Hangzhou Prime Life Sciences Co., Ltd. ("PRIMEAI"), a China-based digital clinical operations innovator focused on AI-native clinical trial infrastructure, announced the first close of its nearly RMB 100 million A1 round financing. The round was led by CICC Capital, with participation from Sumitomo Corporation Equity Asia Limited, Suzhou High-Tech Rongsheng and other institutional investors; proceeds will be used primarily to expand the company's AI-native clinical operations network, advance industrial resource integration and accelerate its global business footprint.

TTM Capital, the lead investor in PRIMEAI's Pre-A+ financing in 2023, is an early-stage shareholder of the company. With the addition of new investors in this round, PRIMEAI has brought together a diversified shareholder base spanning Asian industrial capital, leading financial investors and global pharmaceutical/CRO leaders, further reflecting the capital market's sustained recognition of the company's technology path, commercialization capability and long-term value as AI-enabled clinical trial infrastructure, while reinforcing its scarcity value in the sector.

Founded in 2021, PRIMEAI was incubated in China by IQVIA, the global clinical CRO leader, as a domestic digital clinical operations (DCO) innovation company focused on building AI-native clinical trial infrastructure. Grounded in clinical data governance, the company has developed an end-to-end (E2E) intelligent platform built around EMR-to-EDC technology and vertical clinical AI agents, covering core clinical development workflows including patient screening, data capture and entry, quality monitoring and safety management, while advancing clinical trials toward automation, intelligence and end-to-end traceability.

Dr. Zheng Wang, Founder, Chairman and Chief Executive Officer of PRIMEAI, holds a medical doctorate from Shanghai Jiao Tong University School of Medicine and an MBA from Duke University. Prior to founding PRIMEAI, Dr. Wang served as Vice President, Asia Pacific at IQVIA, with responsibilities across strategic planning, investment and M&A, and technology innovation; his career spans clinical medicine, the pharmaceutical industry, business management and artificial intelligence, with a long-standing focus on using data intelligence, compliance systems and AI technologies to upgrade the clinical development model.

TTM Capital has long followed the digitalization and intelligent transformation of clinical trials. In 2023, TTM Capital led PRIMEAI's Pre-A+ financing alongside co-lead investor Qiming Venture Partners. At that stage, PRIMEAI had largely completed the buildout of its end-to-end digital clinical research platform and had begun collaboration and system deployment across more than 30 large tertiary hospitals in China; since that round, the company has progressed from platform construction and early scenario validation into scaled commercial delivery.

PRIMEAI has independently developed a product system for clinical data flow and AI agent orchestration, with AI capabilities extending across the full process from drug discovery to clinical development and serving nearly 300 domestic and international pharmaceutical companies. Following this financing, the company will further expand its clinical institution and project delivery network, continue iterating its AI platform and vertical clinical AI agents, progressively build an end-to-end delivery system combining an AI platform with a clinical operations network, and accelerate the deployment of global multicenter projects and diversified collaboration models.

Zheng Wang, Founder, Chairman and Chief Executive Officer of PRIMEAI, said:

"AI-driven clinical development is a sector with exceptionally high integrated industrial and technical barriers, as well as strong demand for AI-enabled transformation across the upstream and downstream value chain. PRIMEAI has the capacity to combine endurance and breakout growth across different stages of development. The company plans to integrate offline clinical execution resources and connect the full industry chain spanning an online AI platform and offline clinical operations."

Lily Zhang, Founder & CEO, TTM Capital, said:

"We sincerely congratulate PRIMEAI on the successful completion of this financing. As an early supporter and the lead investor in the company's Pre-A+ round, TTM Capital made a forward-looking commitment to the role of artificial intelligence and digital technologies in empowering the full clinical trial workflow, and we have witnessed PRIMEAI's continued breakthroughs in platform buildout, commercial delivery and partnerships with global pharmaceutical companies. The successful close of this round, together with the endorsement of a broadened group of new shareholders, further validates the long-term value of PRIMEAI's technology path and business model. We believe continued product iteration and industrial resource integration will support PRIMEAI in becoming an important clinical development infrastructure platform serving global pharmaceutical innovation."

TTM Capital will continue our dedication to focus on technology innovation driven by real clinical needs and industry pain points, with a commitment to supporting outstanding teams capable of long-term value creation. By establishing deep partnerships at the early stages of company development and providing sustained support and industry resources, TTM Capital works alongside portfolio companies to accelerate the clinical translation and scalable commercialization of breakthrough innovations.

About PRIMEAI

PRIMEAI is an AI CRO companyfocused on building AI-native clinical trial infrastructure. Through its end-to-end clinical data platform and AI agent system, the company connects hospital clinical data, clinical research institutions and pharmaceutical companies, providing intelligent solutions for patient screening, electronic source data capture, data entry, quality monitoring and safety management across clinical research workflows.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.